LumiraDx Valuation
| LMDXDelisted Stock | USD 0.42 0.02 4.55% |
LumiraDx is overvalued. LumiraDx secures a last-minute Real Value of $0.38 per share. The latest price of the firm is $0.42. Our model forecasts the value of LumiraDx from analyzing the firm fundamentals such as Current Valuation of 440.16 M, profit margin of (2.67) %, and Return On Equity of -15.64 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that LumiraDx's price fluctuation is very steady at this time. Calculation of the real value of LumiraDx is based on 3 months time horizon. Increasing LumiraDx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since LumiraDx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of LumiraDx Stock. However, LumiraDx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.42 | Real 0.38 | Hype 0.42 | Naive 0.39 |
The intrinsic value of LumiraDx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence LumiraDx's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of LumiraDx helps investors to forecast how LumiraDx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of LumiraDx more accurately as focusing exclusively on LumiraDx's fundamentals will not take into account other important factors: LumiraDx Total Value Analysis
LumiraDx is now forecasted to have valuation of 440.16 M with market capitalization of 249.63 M, debt of 401.25 M, and cash on hands of 106.45 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the LumiraDx fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
440.16 M | 249.63 M | 401.25 M | 106.45 M |
LumiraDx Investor Information
About 55.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.08. LumiraDx had not issued any dividends in recent years. Based on the key measurements obtained from LumiraDx's financial statements, LumiraDx is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.LumiraDx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. LumiraDx has an asset utilization ratio of 57.7 percent. This suggests that the Company is making $0.58 for each dollar of assets. An increasing asset utilization means that LumiraDx is more efficient with each dollar of assets it utilizes for everyday operations.LumiraDx Ownership Allocation
LumiraDx maintains a total of 161.02 Million outstanding shares. LumiraDx holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.LumiraDx Profitability Analysis
The company reported the previous year's revenue of 254.48 M. Net Loss for the year was (449.19 M) with profit before overhead, payroll, taxes, and interest of 61.02 M.About LumiraDx Valuation
Our relative valuation model uses a comparative analysis of LumiraDx. We calculate exposure to LumiraDx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of LumiraDx's related companies.LumiraDx Limited operates as a point of care diagnostics company. The company was founded in 2014 and is headquartered in London, the United Kingdom. Lumiradx is traded on NASDAQ Exchange in the United States.
LumiraDx Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 282.2 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in LumiraDx Stock
If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |